- Retrospective administrative claims study showed hospitalizations and related costs dropped significantly after starting PAH-specific therapy
- Pharmacy costs increased significantly, so that all-cause total healthcare costs remained the same
- Decreased costs of healthcare utilization can offset large upfront pharmacy costs
- More studies needed to evaluate practice changes/costs given post-AMBITION recommendations advising initial combination therapy
1. Burger CD, Ozbay AB, Lazarus HM, et al. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States. J Manag Care Spec Pharm. 2018;13:1-9. doi: 10.18553/jmcp.2018.17391.
2. Galiè N, Barbera JA, Frost AE, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834-44.
3. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67-119.
4. Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2015;46:903 -75.